Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 141   

Articles published

NVS 94.79 -0.19 (-0.20%)
price chart
Novartis' (NVS) Signifor Wins EU Approval For Rare Hormonal Disorder
Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Monday that the European Commission has approved its drug Signifor for the treatment of a rare hormonal disorder that is believed to affect about 1-2 in every 10,000 ...
Related articles »  
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Related articles »  
Novartis (NVS) Receives CHMP's Approval For Psoriasis Drug
Novartis AG (ADR) (NYSE:NVS) announced today that secukinumab has received positive feedback from the European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate-to-severe plaque ...
Related articles »  
Novartis AG (ADR) (NVS) Beats Analyst Estimates; Is Expected To Perform Well ...
On the deal between Novartis AG (ADR) (NYSE:NVS) and Google Inc. (NASDAQ:GOOGL), Rundquist said that the deal is interesting for both the companies and the deal represents a new way to thinking in healthcare, by combining bio-technology healthcare ...
Related articles »  
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Related articles »  
Watch List Highlights - Novartis AG (ADR) (NYSE:NVS), Receptos Inc (NASDAQ ...
Novartis AG (ADR) (NYSE:NVS), the global pharmaceuticals company posted Q3 earnings and sales that topped estimates.
Related articles »  
Foreign Companies News: Rio Tinto plc (ADR) (RIO), Novartis AG (ADR) (NVS ...
Novartis AG (ADR) (NYSE:NVS) posted second-quarter results today, and profits missed analyst estimates. The world's largest drugmaker by sales reported a 2% increase in sales, to $14.6 billion, missing analysts' projections of $14.8 billion, and a 3% ...
Related articles »  
Google Inc (GOOGL) and Novartis AG (ADR) (NVS) Join Hands to Develop ...
Tech giants are now focusing excessively on wearables that can help users to track health-related issues. According to a report by Bloomberg, Google Inc (NASDAQ:GOOGL) and Novartis AG (ADR) (NYSE:NVS) now have a deal according to which both ...
Related articles »  
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Related articles »